The Diabetic Macular Edema Market Size is valued at USD 3.95 billion in 2023 and is predicted to reach USD 4.56 billion by the year 2031 at a 1.9% CAGR during the forecast period for 2024-2031.
Diabetic Macular Edema (DME) is an ocular disorder associated with diabetes, characterized by fluid accumulation in the macula, resulting in swelling and impaired central vision. If untreated, it may result in visual loss; however, therapy alternatives exist to mitigate swelling and protect sight.
Hence, the adoption of Diabetic Macular Edema is expected to increase in the near future as concerns grow over diabetic patients. Growing risk factors such as aflibercept, bevacizumab, and ranibizumab are factors expected to drive the growth of the global Diabetic Macular Edema market. The investment in the healthcare sector is another factor expected to augment the target market growth. The increasing research and development activities globally are expected to boost market expansion in the coming years.
Although the COVID-19 pandemic and the high cost of treating diabetic macular edema could limit the target market's growth during the forecast period, rising R&D activities, government policies to use sustainable components for production, and investments by major players are all anticipated to create lucrative growth opportunities in the revenue for players operating in the global market for diabetic macular edema over the forecast period.
The Diabetic Macular Edema market is segmented based on drug type, form, and distribution channel. The drug types are anti-VEGF, Corticosteroid therapies, and others. By form, the market is segmented into intravitreal injections and intravitreal implants. The distribution channel segment includes hospitals, speciality clinics, and mail-order pharmacies.
The anti-VEGF category is expected to hold a major share of the global Diabetic Macular Edema market in 2023. This is attributed to the growing usage of these drugs due to their work by the selective reserve of vascular endothelial growth factor. Additionally, the latest anti-VEGF drug formulations have offered improved efficacy and treatment intervals.
The intravitreal injections segment is projected to grow at a rapid rate in the global Diabetic Macular Edema market owing to growing concerns for the treatment of diabetic macular edema. Hence, with the growing cases of diabetic patients and the safety and tolerability of intravitreal injections, there is an increase in demand for Diabetic Macular Edema in the healthcare.
In the near future, the North American Diabetic Macular Edema market is likely to have the biggest revenue share of the market. This can be attributed to the strong focus on diabetic patients' health in the region, with the increasing adoption of Diabetic Macular Edema to cure the eye disease. In addition, the drug industry in the region is focusing on the production of Diabetic Macular Edema to develop sustainable and environmentally friendly solutions. Moreover, the presence of sophisticated photocoagulation laser manufacturers in the region is a factor in increasing the growth of the target market. In addition, Europe is projected to to see rapid growth in the global diabetic macular edema market due to growing concerns about diabetic patients, rising drug expenditure, government initiatives, and increasing funding in various industries.
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 3.95 Bn |
|
Revenue Forecast In 2031 |
USD 4.56 Bn |
|
Growth Rate CAGR |
CAGR of 1.9% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
Drug Type, Form, And Distribution Channel |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Novartis AG, Bayer AG, Allergan Plc, F. Hoffmann-La Roche Ltd., Alimera Sciences Inc., Valeant Pharmaceuticals International, Inc., KalVista Pharmaceuticals, Genentech, Oxurion, Ocugen, Inc., Regeneron Pharmaceuticals, Inc., Clearside Biomedical, Daiichi Sankyo, Arctic Vision, Chugai Pharmaceutical Co., Ltd. And Other market players |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Diabetic Macular Edema Market Snapshot
Chapter 4. Global Diabetic Macular Edema Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2031
4.8. Global Diabetic Macular Edema Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.10. Use/impact of AI on Diabetic Macular Edema Industry Trends
Chapter 5. Diabetic Macular Edema Market Segmentation 1: By Drug, Estimates & Trend Analysis
5.1. Market Share by Drug, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Drug
5.2.1. Anti-VEGF
5.2.1.1. Ranibizumab (Lucentis)
5.2.1.2. Aflibercept (Eylea)
5.2.2. Corticosteroid Therapies
5.2.2.1. Dexamethasone (Ozurdex)
5.2.2.2. Fluocinolone Acetonide (Iluvien)
5.2.3. Others
Chapter 6. Diabetic Macular Edema Market Segmentation 2: By Form, Estimates & Trend Analysis
6.1. Market Share by Form, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Forms:
6.2.1. Intravitreal Injections
6.2.2. Intravitreal Implants
Chapter 7. Diabetic Macular Edema Market Segmentation 3: By Distribution Channel, Estimates & Trend Analysis
7.1. Market Share by Distribution Channel, 2023 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Distribution Channel:
7.2.1. Hospitals
7.2.2. Specialty Clinics
7.2.3. Mail Order Pharmacies
Chapter 8. Diabetic Macular Edema Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. Global Diabetic Macular Edema Market, Regional Snapshot 2023 & 2031
8.2. North America
8.2.1. North America Diabetic Macular Edema Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
8.2.1.1. US
8.2.1.2. Canada
8.2.2. North America Diabetic Macular Edema Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2024-2031
8.2.3. North America Diabetic Macular Edema Market Revenue (US$ Million) Estimates and Forecasts by Form, 2024-2031
8.2.4. North America Diabetic Macular Edema Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
8.3. Europe
8.3.1. Europe Diabetic Macular Edema Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
8.3.1.1. Germany
8.3.1.2. U.K.
8.3.1.3. France
8.3.1.4. Italy
8.3.1.5. Spain
8.3.1.6. Rest of Europe
8.3.2. Europe Diabetic Macular Edema Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2024-2031
8.3.3. Europe Diabetic Macular Edema Market Revenue (US$ Million) Estimates and Forecasts by Form, 2024-2031
8.3.4. Europe Diabetic Macular Edema Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
8.4. Asia Pacific
8.4.1. Asia Pacific Diabetic Macular Edema Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
8.4.1.1. India
8.4.1.2. China
8.4.1.3. Japan
8.4.1.4. Australia
8.4.1.5. South Korea
8.4.1.6. Hong Kong
8.4.1.7. Southeast Asia
8.4.1.8. Rest of Asia Pacific
8.4.2. Asia Pacific Diabetic Macular Edema Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2024-2031
8.4.3. Asia Pacific Diabetic Macular Edema Market Revenue (US$ Million) Estimates and Forecasts by Form, 2024-2031
8.4.4. Asia Pacific Diabetic Macular Edema Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
8.5. Latin America
8.5.1. Latin America Diabetic Macular Edema Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
8.5.1.1. Brazil
8.5.1.2. Mexico
8.5.1.3. Rest of Latin America
8.5.2. Latin America Diabetic Macular Edema Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2024-2031
8.5.3. Latin America Diabetic Macular Edema Market Revenue (US$ Million) Estimates and Forecasts by Form, 2024-2031
8.5.4. Latin America Diabetic Macular Edema Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
8.6. Middle East & Africa
8.6.1. Middle East & Africa Diabetic Macular Edema Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.6.1.1. GCC Countries
8.6.1.2. Israel
8.6.1.3. South Africa
8.6.1.4. Rest of Middle East and Africa
8.6.2. Middle East & Africa Diabetic Macular Edema Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2024-2031
8.6.3. Middle East & Africa Diabetic Macular Edema Market Revenue (US$ Million) Estimates and Forecasts by Form, 2024-2031
8.6.4. Middle East & Africa Diabetic Macular Edema Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Novartis AG
9.2.1.1. Business Overview
9.2.1.2. Key Product/Service Offerings
9.2.1.3. Financial Performance
9.2.1.4. Geographical Presence
9.2.1.5. Recent Developments with Business Strategy
9.2.2. Bayer AG
9.2.3. Allergan Plc.
9.2.4. F. Hoffmann-La Roche Ltd.
9.2.5. Alimera Sciences Inc.
9.2.6. Valeant Pharmaceuticals International, Inc. (Bausch & Lomb Inc.)
9.2.7. KalVista Pharmaceuticals
9.2.8. Genentech
9.2.9. Oxurion (fka ThromboGenics)
9.2.10. Ocugen, Inc
9.2.11. Regeneron Pharmaceuticals, Inc.
9.2.12. Clearside Biomedical
9.2.13. Daiichi Sankyo
9.2.14. Arctic Vision
9.2.15. Chugai Pharmaceutical Co., Ltd.
9.2.16. Sanofi
9.2.17. Novartis AG
9.2.18. Sun Pharmaceutical Industries Ltd.
9.2.19. Aurobindo Pharma
9.2.20. Lupin
9.2.21. Allergan
9.2.22. Merck & Co., Inc.
9.2.23. Pfizer Inc.
9.2.24. GlaxoSmithKline plc
9.2.25. IRIDEX Corporation
9.2.26. Other Prominent Players
Diabetic Macular Edema Market By Drug Type-
Diabetic Macular Edema Market By Form-
Diabetic Macular Edema Market By Distribution Channel-
Diabetic Macular Edema Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Rest of Middle East and Africa
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
